CLC COMMENTS RE CMS PROPOSED DECISION MEMORANDUM
May 9, 2007
Many CLC members have worked for years not just to achieve the Medicare policy on clinical trials but also to obtain passage of state legislation modeled after that policy. We are very disappointed to see that the Centers for Medicare & Medicaid Services (CMS) has deleted an important element of the policy, coverage for IND exempt trials, without offering a satisfactory justification. The Food and Drug Administration (FDA) has made a science-based decision that IND exempt trials do not require the same level of oversight as other trials, and CMS should respect that decision. These trials offer important treatment options for many patients, and they also provide incremental advances in our knowledge of how chemotherapy drugs may be best utilized. It is not insignificant that, as CMS acknowledges, every comment submitted on this topic advocated retaining the automatic coverage of IND exempt trials.
CMS committed to the development of a self-certification process for these trials, but no such process has emerged. We feel that it is not an acceptable response for CMS simply to abandon coverage for IND exempt trials without further consideration of methods for assuring that these trials are appropriately covered – though we firmly believe that FDA’s judgment on this issue should be controlling.
Finally, this category of trial has special – perhaps unique – significance for cancer treatment, and we urge CMS to seriously consider continuing the “deemed” coverage status of IND exempt cancer trials, even if a decision is made to eliminate coverage of other IND exempt trials.
© 2001-2002 Cancer Leadership Council. All rights reserved.